Search Results - "Ascierto, Paolo A."

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape by Emens, Leisha A, Ascierto, Paolo A, Darcy, Phillip K, Demaria, Sandra, Eggermont, Alexander M.M, Redmond, William L, Seliger, Barbara, Marincola, Francesco M

“…Abstract Cancer immunotherapy is now established as a powerful way to treat cancer. The recent clinical success of immune checkpoint blockade (antagonists of…”
Get full text

The influence of diet on anti-cancer immune responsiveness by Soldati, Laura, Di Renzo, Laura, Jirillo, Emilio, Ascierto, Paolo A, Marincola, Francesco M, De Lorenzo, Antonino

“…Immunotherapy has matured into standard treatment for several cancers, but much remains to be done to extend the reach of its effectiveness particularly to…”
Get full text

Systemic Therapy for Melanoma: ASCO Guideline by Seth, Rahul, Messersmith, Hans, Kaur, Varinder, Kirkwood, John M, Kudchadkar, Ragini, McQuade, Jennifer Leigh, Provenzano, Anthony, Swami, Umang, Weber, Jeffrey, Alluri, Krishna C, Agarwala, Sanjiv, Ascierto, Paolo A, Atkins, Michael B, Davis, Nancy, Ernstoff, Marc S, Faries, Mark B, Gold, Jason S, Guild, Samantha, Gyorki, David E, Khushalani, Nikhil I, Meyers, Michael O, Robert, Caroline, Santinami, Mario, Sehdev, Amikar, Sondak, Vernon K, Spurrier, Gilliosa, Tsai, Katy K, van Akkooi, Alexander, Funchain, Pauline

“…To provide guidance to clinicians regarding the use of systemic therapy for melanoma. ASCO convened an Expert Panel and conducted a systematic review of the…”
Get full text

Immunological effects of BRAF+MEK inhibition by Ascierto, Paolo A., Dummer, Reinhard

“…Recent developments in immunotherapy have prolonged overall survival in metastatic melanoma with the possibility to reach a long-term benefit. Targeted…”
Get full text

PD-1 Blockade in Anaplastic Thyroid Carcinoma by Capdevila, Jaume, Wirth, Lori J, Ernst, Thomas, Ponce Aix, Santiago, Lin, Chia-Chi, Ramlau, Rodryg, Butler, Marcus O, Delord, Jean-Pierre, Gelderblom, Hans, Ascierto, Paolo A, Fasolo, Angelica, Führer, Dagmar, Hütter-Krönke, Marie Luise, Forde, Patrick M, Wrona, Anna, Santoro, Armando, Sadow, Peter M, Szpakowski, Sebastian, Wu, Hongqian, Bostel, Geraldine, Faris, Jason, Cameron, Scott, Varga, Andreea, Taylor, Matthew

“…Anaplastic thyroid carcinoma is an aggressive malignancy that is almost always fatal and lacks effective systemic treatment options for patients with -wild…”
Get full text

Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma by Ascierto, Paolo A, Schadendorf, Dirk

“…Non-melanoma skin cancer (NMSC) includes a wide range of cutaneous tumors, the most frequent of which are basal cell carcinoma (BCC) and cutaneous squamous…”
Get full text

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial by Antonia, Scott J, Prof, López-Martin, José A, MD, Bendell, Johanna, MD, Ott, Patrick A, MD, Taylor, Matthew, MD, Eder, Joseph Paul, MD, Jäger, Dirk, MD, Pietanza, M Catherine, MD, Le, Dung T, MD, de Braud, Filippo, Prof, Morse, Michael A, Prof, Ascierto, Paolo A, MD, Horn, Leora, MD, Amin, Asim, MD, Pillai, Rathi N, MD, Evans, Jeffry, Prof, Chau, Ian, MD, Bono, Petri, MD, Atmaca, Akin, MD, Sharma, Padmanee, Prof, Harbison, Christopher T, PhD, Lin, Chen-Sheng, PhD, Christensen, Olaf, MD, Calvo, Emiliano, Dr

“…Summary Background Treatments for small-cell lung cancer (SCLC) after failure of platinum-based chemotherapy are limited. We assessed safety and activity of…”
Get full text

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial by Weber, Jeffrey S, Dr, D'Angelo, Sandra P, MD, Minor, David, MD, Hodi, F Stephen, MD, Gutzmer, Ralf, MD, Neyns, Bart, MD, Hoeller, Christoph, MD, Khushalani, Nikhil I, MD, Miller, Wilson H, MD, Lao, Christopher D, MD, Linette, Gerald P, MD, Thomas, Luc, MD, Lorigan, Paul, FRCP, Grossmann, Kenneth F, MD, Hassel, Jessica C, MD, Maio, Michele, MD, Sznol, Mario, MD, Ascierto, Paolo A, MD, Mohr, Peter, MD, Chmielowski, Bartosz, MD, Bryce, Alan, MD, Svane, Inge M, MD, Grob, Jean-Jacques, MD, Krackhardt, Angela M, MD, Horak, Christine, PhD, Lambert, Alexandre, PhD, Yang, Arvin S, MD, Larkin, James, FRCP

“…Summary Background Nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, can result in durable responses in patients with melanoma who have…”
Get full text

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial by Ribas, Antoni, Prof, Puzanov, Igor, MD, Dummer, Reinhard, Prof, Schadendorf, Dirk, Prof, Hamid, Omid, MD, Robert, Caroline, Prof, Hodi, F Stephen, MD, Schachter, Jacob, Prof, Pavlick, Anna C, MD, Lewis, Karl D, MD, Cranmer, Lee D, MD, Blank, Christian U, MD, O'Day, Steven J, MD, Ascierto, Paolo A, Prof, Salama, April K S, MD, Margolin, Kim A, Prof, Loquai, Carmen, MD, Eigentler, Thomas K, MD, Gangadhar, Tara C, MD, Carlino, Matteo S, MBBS, Agarwala, Sanjiv S, Prof, Moschos, Stergios J, MD, Sosman, Jeffrey A, Prof, Goldinger, Simone M, MD, Shapira-Frommer, Ronnie, MD, Gonzalez, Rene, Prof, Kirkwood, John M, Prof, Wolchok, Jedd D, Prof, Eggermont, Alexander, Prof, Li, Xiaoyun Nicole, PhD, Zhou, Wei, PhD, Zernhelt, Adriane M, BS, Lis, Joy, BSN, Ebbinghaus, Scot, MD, Kang, S Peter, MD, Daud, Adil, Prof

“…Summary Background Patients with melanoma that progresses on ipilimumab and, if BRAFV600 mutant-positive, a BRAF or MEK inhibitor or both, have few treatment…”
Get full text

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort by Ready, Neal E, Ott, Patrick A, Hellmann, Matthew D, Zugazagoitia, Jon, Hann, Christine L, de Braud, Filippo, Antonia, Scott J, Ascierto, Paolo A, Moreno, Victor, Atmaca, Akin, Salvagni, Stefania, Taylor, Matthew, Amin, Asim, Camidge, D Ross, Horn, Leora, Calvo, Emiliano, Li, Ang, Lin, Wen Hong, Callahan, Margaret K, Spigel, David R

“…Nivolumab monotherapy is approved in the United States for third-line or later metastatic small cell lung cancer based on pooled data from nonrandomized and…”
Get more information

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial by Eggermont, Alexander M M, Prof, Chiarion-Sileni, Vanna, MD, Grob, Jean-Jacques, Prof, Dummer, Reinhard, Prof, Wolchok, Jedd D, MD, Schmidt, Henrik, MD, Hamid, Omid, MD, Robert, Caroline, Prof, Ascierto, Paolo A, Prof, Richards, Jon M, MD, Lebbé, Céleste, Prof, Ferraresi, Virginia, MD, Smylie, Michael, MD, Weber, Jeffrey S, MD, Maio, Michele, MD, Konto, Cyril, MD, Hoos, Axel, MD, de Pril, Veerle, MSc, Gurunath, Ravichandra Karra, MD, de Schaetzen, Gaetan, PhD, Suciu, Stefan, PhD, Testori, Alessandro, MD

“…Summary Background Ipilimumab is an approved treatment for patients with advanced melanoma. We aimed to assess ipilimumab as adjuvant therapy for patients with…”
Get full text

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF -Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial by Ascierto, Paolo A, Mandalà, Mario, Ferrucci, Pier Francesso, Guidoboni, Massimo, Rutkowski, Piotr, Ferraresi, Virginia, Arance, Ana, Guida, Michele, Maiello, Evaristo, Gogas, Helen, Richtig, Erika, Fierro, Maria Teresa, Lebbè, Celeste, Helgadottir, Hildur, Queirolo, Paola, Spagnolo, Francesco, Tucci, Marco, Del Vecchio, Michele, Gonzales Cao, Maria, Minisini, Alessandro Marco, De Placido, Sabino, Sanmamed, Miguel F, Mallardo, Domenico, Curvietto, Marcello, Melero, Ignacio, Palmieri, Giuseppe, Grimaldi, Antonio M, Giannarelli, Diana, Dummer, Reinhard, Chiarion Sileni, Vanna

“…Limited prospective data are available on sequential immunotherapy and BRAF/MEK inhibition for -mutant metastatic melanoma. SECOMBIT is a randomized,…”
Get full text

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial by Ascierto, Paolo A, Dr, Del Vecchio, Michele, MD, Robert, Caroline, Prof, Mackiewicz, Andrzej, Prof, Chiarion-Sileni, Vanna, MD, Arance, Ana, MD, Lebbé, Céleste, Prof, Bastholt, Lars, MD, Hamid, Omid, MD, Rutkowski, Piotr, Prof, McNeil, Catriona, MD, Garbe, Claus, Prof, Loquai, Carmen, MD, Dreno, Brigitte, Prof, Thomas, Luc, Prof, Grob, Jean-Jacques, Prof, Liszkay, Gabriella, Prof, Nyakas, Marta, MD, Gutzmer, Ralf, Prof, Pikiel, Joanna, MD, Grange, Florent, MD, Hoeller, Christoph, MD, Ferraresi, Virginia, MD, Smylie, Michael, MD, Schadendorf, Dirk, Prof, Mortier, Laurent, Prof, Svane, Inge Marie, MD, Hennicken, Delphine, MSc, Qureshi, Anila, MD, Maio, Michele, MD

“…Summary Background A phase 2 trial suggested increased overall survival and increased incidence of treatment-related grade 3–4 adverse events with ipilimumab…”
Get full text

Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial by Dummer, Reinhard, Prof, Schadendorf, Dirk, Prof, Ascierto, Paolo A, MD, Arance, Ana, MD, Dutriaux, Caroline, MD, Di Giacomo, Anna Maria, MD, Rutkowski, Piotr, Prof, Del Vecchio, Michele, MD, Gutzmer, Ralf, Prof, Mandala, Mario, MD, Thomas, Luc, Prof, Demidov, Lev, Prof, Garbe, Claus, Prof, Hogg, David, MD, Liszkay, Gabriella, Prof, Queirolo, Paola, MD, Wasserman, Ernesto, MD, Ford, James, MS, Weill, Marine, MSc, Sirulnik, L Andres, MD, Jehl, Valentine, MSc, Bozón, Viviana, MD, Long, Georgina V, Prof, Flaherty, Keith, MD

“…Summary Background There are no established therapies specific for NRAS -mutant melanoma despite the emergence of immunotherapy. We aimed to assess the…”
Get full text

The immune score as a new possible approach for the classification of cancer by Galon, Jérôme, Pagès, Franck, Marincola, Francesco M, Thurin, Magdalena, Trinchieri, Giorgio, Fox, Bernard A, Gajewski, Thomas F, Ascierto, Paolo A

“…The outcome prediction in cancer is usually achieved by evaluating tissue samples obtained during surgical removal of the primary tumor focusing on their…”
Get full text

MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors by Grimaldi, Antonio M., Simeone, Ester, Festino, Lucia, Vanella, Vito, Strudel, Martina, Ascierto, Paolo A.

“…The mitogen-activated protein kinase (MAPK) cascade is an intracellular signaling pathway involved in the regulation of cellular proliferation and the survival…”
Get full text

Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma by ASCIERTO, Paolo A, MINOR, David, HAMID, Omid, AMARAVADI, Ravi, SIMEONE, Ester, WILHELM, Tabea, KIM, Kevin B, LONG, Georgina V, MARTIN, Anne-Marie, MAZUMDAR, Jolly, GOODMAN, Vicki L, TREFZER, Uwe, RIBAS, Antoni, LEBBE, Celeste, O'HAGAN, Anne, ARYA, Niki, GUCKERT, Mary, SCHADENDORF, Dirk, KEFFORD, Richard F, GROB, Jean-Jacques

“…Dabrafenib (GSK2118436) is a potent inhibitor of mutated BRAF kinase. Our multicenter, single-arm, phase II study assessed the safety and clinical activity of…”
Get full text

Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination by MELERO, Ignacio, GRIMALDI, Antonio M, PEREZ-GRACIA, Jose L, ASCIERTO, Paolo A

“…Immune system responses are under the control of extracellular biomolecules, which express functions in receptors present on the surface of cells of the immune…”
Get full text

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial by Long, Georgina V, Dr, Trefzer, Uwe, MD, Davies, Michael A, MD, Kefford, Richard F, Prof, Ascierto, Paolo A, MD, Chapman, Paul B, MD, Puzanov, Igor, MD, Hauschild, Axel, MD, Robert, Caroline, PhD, Algazi, Alain, MD, Mortier, Laurent, Prof, Tawbi, Hussein, PhD, Wilhelm, Tabea, MD, Zimmer, Lisa, MD, Switzky, Julie, MSN, Swann, Suzanne, PhD, Martin, Anne-Marie, PhD, Guckert, Mary, MSN, Goodman, Vicki, MD, Streit, Michael, MD, Kirkwood, John M, Prof, Schadendorf, Dirk, Prof

“…Summary Background Brain metastases are common in patients with metastatic melanoma and median overall survival from their diagnosis is typically 17–22 weeks…”
Get full text

Immuno-oncology combinations: a review of clinical experience and future prospects by Antonia, Scott J, Larkin, James, Ascierto, Paolo A

“…Immuno-oncology is an evolving treatment modality that includes immunotherapies designed to harness the patient's own immune system. This approach is being…”
Get full text